Virbac SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Paul Martingell
- Full Time Employees
- 6,442
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 13e rue LID - BP 27 Carros PA France 06511
- IPO Date
- Jan 1, 1985
- Website
- virbac.fr
- Similar Companies
- Business
- Virbac S.A. operates as a global force in veterinary healthcare, offering a wide array of products and services designed for both companion animals and those used in food production across Europe, North America, Latin America, Asia-Pacific, the Middle East, and Africa. The company delivers essential pharmaceuticals, vaccines, and advanced diagnostic tools. Its extensive portfolio encompasses solutions for parasiticides, dermatology, dental hygiene, reproduction, antibiotics, and anti-inflammatory medications. Additionally, Virbac provides specialized nutrition including pet food, aquaculture treatments, and electronic identification systems. These offerings address core pathologies and enhance the well-being of dogs, cats, horses, poultry, cattle, and swine. Serving veterinarians, farmers, and pet owners, Virbac is committed to advancing animal health through innovation and a customer-centric approach. Recent strategic moves include acquisitions like Globion, an Indian poultry vaccine specialist, and Sasaeah in Japan, a key player in farm animal vaccines. The company, established in 1968, maintains its headquarters in Carros, France.
Company News
Virbac SA (VRBCF) Q2 2026 Earnings Call Transcript
Virbac confirms outlook as Supercharge platforms drive profit growth
Virbac : Declaration of the number of shares and voting rights 05/2026
Virbac : Declaration of the number of shares and voting rights 04/2026
Virbac : Public release of Virbac Annual Report at 31 December 2025.
Virbac: strong Q1 2026 growth of +7.7% at CERS, driven by double-digit growth of our priority Supercharge4 platforms
Virbac : Declaration of the number of shares and voting rights 03/2026
Virbac SA (VRBCF) Q4 2025 Earnings Call Transcript
Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2025
Virbac: 2025 annual results
Virbac : Declaration of the number of shares and voting rights 02/2026
Virbac : Declaration of the number of shares and voting rights 01/2026
Virbac : Declaration of the number of shares and voting rights 11/2025
VIRBAC Announces Third Quarter 2025 Sales
Virbac SA (VRBCF) Q2 2025 Earnings Call Transcript
Virbac: 2025 Half-year results
Virbac : Public release of the Half-Year Financial Report at 30 June 2025.
Virbac : Half-yearly financial report 2025
Virbac:: Paul Martingell's compensation terms
Virbac: in the first half of 2025, revenue recorded solid growth of +5.6% at constant exchange rates and scope of consolidation